Suppr超能文献

Lgr5表达增加与人类胃癌的化疗耐药相关。

Increased expression of Lgr5 is associated with chemotherapy resistance in human gastric cancer.

作者信息

Xi Hong-Qing, Cui Jian-Xin, Shen Wei-Song, Wu Xiao-Song, Bian Shi-Bo, Li Ji-Yang, Song Zhou, Wei Bo, Chen Lin

机构信息

Department of General Surgery, Chinese People's Liberation Army General Hospital, Beijing 100853, P.R. China.

出版信息

Oncol Rep. 2014 Jul;32(1):181-8. doi: 10.3892/or.2014.3207. Epub 2014 May 22.

Abstract

Leucine-rich repeat-containing G protein-coupled receptor 5 (Lgr5), a marker of adult stem cells and cancer stem cells, plays important roles in tumor progression. Furthermore, Lgr5 also contributes to chemoradiotherapy resistance. However, the function of Lgr5 in the prediction of preoperative chemotherapy efficacy has not been reported. We evaluated the potential of Lgr5 in predicting tumor response and overall survival in advanced gastric cancer treated with preoperative chemotherapy. The association between Lgr5 and chemotherapy resistance was also investigated in gastric cancer cell lines. Hematoxylin and eosin staining and immunohistochemical analysis of Lgr5 expression were performed in 68 cases of gastric cancer treated with preoperative chemotherapy. Lgr5 expression was specifically silenced in the AGS gastric cancer cell lines by RNA interference. Levels of Lgr5 mRNA and protein in cell lines were detected by quantitative reverse transcription-polymerase chain reaction or western blotting. Cell viability was evaluated by an MTT assay. Cell apoptosis was assessed by Annexin V-FITC/propidium iodide dual staining analysis. We found that Lgr5 expression was significantly associated with tumor regression grade after preoperative chemotherapy. The rate of positive Lgr5 expression was significantly higher in patients with poor tumor regression compared with those exhibiting tumor regression (P=0.001). Lgr5-positive patients had a significantly shorter survival time than Lgr5-negative patients (P=0.001). Inhibition of Lgr5 expression with small interfering RNA increased the sensitivity of AGS gastric cancer cells to chemotherapy. Our findings suggest that Lgr5 expression may be implicated in the chemoresistance of gastric cancer cells and is a potential novel biomarker for predicting response to chemotherapy and prognosis in gastric cancer patients, and may also represent a potential new therapeutic target for cancer therapy.

摘要

富含亮氨酸重复序列的G蛋白偶联受体5(Lgr5)是成体干细胞和癌症干细胞的标志物,在肿瘤进展中起重要作用。此外,Lgr5也导致放化疗耐药。然而,Lgr5在预测术前化疗疗效方面的功能尚未见报道。我们评估了Lgr5在预测术前化疗的晚期胃癌患者肿瘤反应和总生存方面的潜力。还在胃癌细胞系中研究了Lgr5与化疗耐药之间的关联。对68例接受术前化疗的胃癌患者进行苏木精-伊红染色及Lgr5表达的免疫组化分析。通过RNA干扰在AGS胃癌细胞系中特异性沉默Lgr5表达。采用定量逆转录-聚合酶链反应或蛋白质印迹法检测细胞系中Lgr5 mRNA和蛋白水平。通过MTT法评估细胞活力。采用膜联蛋白V-异硫氰酸荧光素/碘化丙啶双染分析评估细胞凋亡。我们发现,Lgr5表达与术前化疗后的肿瘤退缩分级显著相关。与肿瘤有退缩的患者相比,肿瘤退缩差的患者中Lgr5阳性表达率显著更高(P = 0.001)。Lgr5阳性患者的生存时间显著短于Lgr5阴性患者(P = 0.001)。用小干扰RNA抑制Lgr5表达可增加AGS胃癌细胞对化疗的敏感性。我们的研究结果表明,Lgr5表达可能与胃癌细胞的化疗耐药有关,是预测胃癌患者化疗反应和预后的潜在新型生物标志物,也可能是癌症治疗的潜在新靶点。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验